Jonathan Lim, Co-Lead of The Manchester Immuno-Oncology Network (MION) and Lead of The Christie International Fellowship Program for Medical Oncology at The Christie NHS Foundation Trust, shared a post on LinkedIn:
“Happy to share a new perspective just out now in British Journal of Cancer on TIL therapy in melanoma.
TIL therapy in melanoma is edging closer to real-world practice (already in the US , The Netherlands and Denmark) – but the how matters just as much as the whether.
In this perspective, we reflect on where the field is heading, and the practical, clinical, and service-level challenges that come with potentially moving TIL therapy from clinical trial settings to routine care.
Keen to hear thoughts or experiences from others working in this area.”
Title: Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time?
Authors: Rachel Woodford, Paul Lorigan, Deemesh Oudit, Ahmed Abdulgawad, Fiona Thistlethwaite, Kok Haw Jonathan Lim
Read The Full Article
Other articles about Melanoma on OncoDaily.